Welcome   Guest   [Login | Register] Sign in with Facebook Sign in with Google Sign in with Yahoo!
OncoMed Pharmaceuticals, Inc. - Common Stock   (ticker: OMED)
Quote:OncoMed Pharmaceuticals Inc.(OMED) OMED Quotes on: Yahoo | Google
0.06 (4%)
5 day's Perf: 82.04%
1 Month Perf: 81.32%
3 Month Perf: 83.46%
YTD Perf: 81.32%
1 Year Perf: 84.96%
Stock chart
Useful Quick Links for OMED
Financial Key Date: Yahoo
Option Prices: MarketWatch
Technical Opinion: Barchar.com
Technical Charts: StockCharts.com
Analyst & Estimates: Reuters
Ratings: TheStreet.com
SEC Filings: EDGAR Online
Message Boards: Yahoo | TheLion
Insiders' Indicator :          Hold          (Click Here For Details)
INSIDERS' Score: 45
0 100 45
Latest 1 month: 0 0
Latest 6 Months: 0 13,905
52 Weeks: 0 35,677
Gurus' Indicator :          Buy          (Click Here For Details)
GURUS' Score: 60
0 100 60
Current Holdings: 1,194,469
Previous Holdings: 1,056,327
Change: 13.08%
Institutions' Indicator :          Hold          (Click Here For Details)
0 100 50
Current Holdings: 18,747,590
Previous Holdings: 18,328,629
Change: 2.29%
News And Links For The Group (Contribute a link)
[OMED]   OncoMed: Undervalued With A Promising Pipeline  (Seeking Alpha)   16-Oct-18 12:19
[OMED]   Compugen, 'From Code To Cure': Becoming A Clinical-Stage Company  (Seeking Alpha)   5-Sep-18 10:11
[OMED]   A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals  (Seeking Alpha)   16-Jun-18 09:00
[OMED]   OncoMed Pharmaceuticals: Assessing The Prospect Of A Potential Robust Winner  (Seeking Alpha)   21-May-18 03:36
[OMED]   Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge  (Seeking Alpha)   31-Mar-18 09:55
[OMED]   Arcus Biosciences Files To Raise $100 Million In IPO  (Seeking Alpha)   23-Feb-18 12:24
==>More News
*Data and information is provided for informational purposes only, and is not intended for trading purposes.*
*By accessing the Relationalstocks.com web site, a user agrees that RelationalStocks.com shall be not liable for any errors or delays in the content.*